Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis

L. Ferrer, J. Alberola, M. Queralt, P. Brazís, R. Rabanal, J. Llenas, A. Puigdemont

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

Forty atopic dogs were studied for 28 days after the oral administration of four randomised treatments: (A) arofylline (1 mg/kg) twice daily for four weeks; (B) prednisone (0.5 mg/kg) twice daily for the first week, once a day during the second week and every 48 hours for the remaining two weeks; (C) prednisone following the same protocol but at a dose of 0.25 mg/kg; or (D) arofylline (1 mg/kg) twice daily for four weeks plus prednisone (0.25 mg/kg) following the same protocol as in (B) and (C). The degree of pruritus and skin lesions and the side effects were evaluated and graded from 0 to 3 before and weekly during the treatments. In all cases there was a progressive clinical improvement in the clinical signs, with no statistical differences among the four treatments. However, many of the dogs treated with arofylline vomited and had adverse gastrointestinal signs.
Original languageEnglish
Pages (from-to)191-194
JournalVeterinary Record
Volume145
Issue number7
DOIs
Publication statusPublished - 14 Aug 1999

Fingerprint Dive into the research topics of 'Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis'. Together they form a unique fingerprint.

Cite this